Cargando…

Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment

There are limited reports regarding early predictors of objective response (OR) in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study including 70 patients aimed to investigate the efficacy of hepatic biochemical markers. Changes in tumor marker (alpha-fet...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeki, Issei, Yamasaki, Takahiro, Yamashita, Satoyoshi, Hanazono, Tadasuke, Urata, Yohei, Furutani, Takakazu, Yokoyama, Yuichiro, Oishi, Toshiyuki, Maeda, Masaki, Kimura, Teruaki, Kotoh, Yurika, Sasaki, Ryo, Miyaji, Takashi, Oono, Takashi, Aibe, Yuki, Hisanaga, Takuro, Iwamoto, Takuya, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225985/
https://www.ncbi.nlm.nih.gov/pubmed/32218295
http://dx.doi.org/10.3390/cancers12040779
_version_ 1783534181057298432
author Saeki, Issei
Yamasaki, Takahiro
Yamashita, Satoyoshi
Hanazono, Tadasuke
Urata, Yohei
Furutani, Takakazu
Yokoyama, Yuichiro
Oishi, Toshiyuki
Maeda, Masaki
Kimura, Teruaki
Kotoh, Yurika
Sasaki, Ryo
Miyaji, Takashi
Oono, Takashi
Aibe, Yuki
Hisanaga, Takuro
Iwamoto, Takuya
Matsumoto, Toshihiko
Hidaka, Isao
Ishikawa, Tsuyoshi
Takami, Taro
Sakaida, Isao
author_facet Saeki, Issei
Yamasaki, Takahiro
Yamashita, Satoyoshi
Hanazono, Tadasuke
Urata, Yohei
Furutani, Takakazu
Yokoyama, Yuichiro
Oishi, Toshiyuki
Maeda, Masaki
Kimura, Teruaki
Kotoh, Yurika
Sasaki, Ryo
Miyaji, Takashi
Oono, Takashi
Aibe, Yuki
Hisanaga, Takuro
Iwamoto, Takuya
Matsumoto, Toshihiko
Hidaka, Isao
Ishikawa, Tsuyoshi
Takami, Taro
Sakaida, Isao
author_sort Saeki, Issei
collection PubMed
description There are limited reports regarding early predictors of objective response (OR) in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study including 70 patients aimed to investigate the efficacy of hepatic biochemical markers. Changes in tumor marker (alpha-fetoprotein (AFP)/des-gamma-carboxy prothrombin (DCP)) levels and albumin–bilirubin (ALBI) score between the baseline value and that estimated one month after treatment were evaluated. We identified several predictors of OR, including changes in tumor marker levels. The OR rate calculated using modified Response Evaluation Criteria in Solid Tumor (mRECIST) was 41.4%. Response was defined as a reduction in AFP and DCP levels of ≥40% from baseline. OR was significantly associated with AFP response, but not with DCP. Predictors of OR were evaluated in two groups (high-AFP group: baseline AFP ≥ 10 ng/mL; low-AFP group: remaining patients). A multivariate analysis identified AFP response (odds ratio, 51.389; p = 0.001) and ALBI score (odds ratio, 6.866; p = 0.039) as independent predictors of OR in the high-AFP and low-AFP groups, respectively. Changes in the ALBI score indicated deterioration in both responders and non-responders, with a significant difference in non-responders (p = 0.003). AFP response, baseline ALBI score, and change in the ALBI score were early predictors of OR in patients with HCC undergoing lenvatinib treatment.
format Online
Article
Text
id pubmed-7225985
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72259852020-05-18 Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment Saeki, Issei Yamasaki, Takahiro Yamashita, Satoyoshi Hanazono, Tadasuke Urata, Yohei Furutani, Takakazu Yokoyama, Yuichiro Oishi, Toshiyuki Maeda, Masaki Kimura, Teruaki Kotoh, Yurika Sasaki, Ryo Miyaji, Takashi Oono, Takashi Aibe, Yuki Hisanaga, Takuro Iwamoto, Takuya Matsumoto, Toshihiko Hidaka, Isao Ishikawa, Tsuyoshi Takami, Taro Sakaida, Isao Cancers (Basel) Article There are limited reports regarding early predictors of objective response (OR) in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study including 70 patients aimed to investigate the efficacy of hepatic biochemical markers. Changes in tumor marker (alpha-fetoprotein (AFP)/des-gamma-carboxy prothrombin (DCP)) levels and albumin–bilirubin (ALBI) score between the baseline value and that estimated one month after treatment were evaluated. We identified several predictors of OR, including changes in tumor marker levels. The OR rate calculated using modified Response Evaluation Criteria in Solid Tumor (mRECIST) was 41.4%. Response was defined as a reduction in AFP and DCP levels of ≥40% from baseline. OR was significantly associated with AFP response, but not with DCP. Predictors of OR were evaluated in two groups (high-AFP group: baseline AFP ≥ 10 ng/mL; low-AFP group: remaining patients). A multivariate analysis identified AFP response (odds ratio, 51.389; p = 0.001) and ALBI score (odds ratio, 6.866; p = 0.039) as independent predictors of OR in the high-AFP and low-AFP groups, respectively. Changes in the ALBI score indicated deterioration in both responders and non-responders, with a significant difference in non-responders (p = 0.003). AFP response, baseline ALBI score, and change in the ALBI score were early predictors of OR in patients with HCC undergoing lenvatinib treatment. MDPI 2020-03-25 /pmc/articles/PMC7225985/ /pubmed/32218295 http://dx.doi.org/10.3390/cancers12040779 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Saeki, Issei
Yamasaki, Takahiro
Yamashita, Satoyoshi
Hanazono, Tadasuke
Urata, Yohei
Furutani, Takakazu
Yokoyama, Yuichiro
Oishi, Toshiyuki
Maeda, Masaki
Kimura, Teruaki
Kotoh, Yurika
Sasaki, Ryo
Miyaji, Takashi
Oono, Takashi
Aibe, Yuki
Hisanaga, Takuro
Iwamoto, Takuya
Matsumoto, Toshihiko
Hidaka, Isao
Ishikawa, Tsuyoshi
Takami, Taro
Sakaida, Isao
Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
title Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
title_full Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
title_fullStr Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
title_full_unstemmed Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
title_short Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
title_sort early predictors of objective response in patients with hepatocellular carcinoma undergoing lenvatinib treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225985/
https://www.ncbi.nlm.nih.gov/pubmed/32218295
http://dx.doi.org/10.3390/cancers12040779
work_keys_str_mv AT saekiissei earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT yamasakitakahiro earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT yamashitasatoyoshi earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT hanazonotadasuke earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT uratayohei earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT furutanitakakazu earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT yokoyamayuichiro earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT oishitoshiyuki earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT maedamasaki earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT kimurateruaki earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT kotohyurika earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT sasakiryo earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT miyajitakashi earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT oonotakashi earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT aibeyuki earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT hisanagatakuro earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT iwamototakuya earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT matsumototoshihiko earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT hidakaisao earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT ishikawatsuyoshi earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT takamitaro earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment
AT sakaidaisao earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment